Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study
Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2015-09-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | http://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-78309&look4= |
| _version_ | 1797723481213763584 |
|---|---|
| author | Hakan Savlı Sara Galimberti Deniz Sünnetçi Martina Canestraro Giuseppe Palumbo Balint Nagy Francesco Di Raimondo Mario Petrini |
| author_facet | Hakan Savlı Sara Galimberti Deniz Sünnetçi Martina Canestraro Giuseppe Palumbo Balint Nagy Francesco Di Raimondo Mario Petrini |
| author_sort | Hakan Savlı |
| collection | DOAJ |
| description | Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39.
Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR.
Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings.
Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS. |
| first_indexed | 2024-03-12T10:02:29Z |
| format | Article |
| id | doaj.art-886f63060f644c19bb2719161c4653d8 |
| institution | Directory Open Access Journal |
| issn | 1300-7777 1308-5263 |
| language | English |
| last_indexed | 2024-03-12T10:02:29Z |
| publishDate | 2015-09-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-886f63060f644c19bb2719161c4653d82023-09-02T11:32:07ZengGalenos Publishing HouseTurkish Journal of Hematology1300-77771308-52632015-09-0132320621210.4274/tjh.2014.0058Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression StudyHakan Savlı0Sara Galimberti1Deniz Sünnetçi2Martina Canestraro3Giuseppe Palumbo4Balint Nagy5Francesco Di Raimondo6Mario Petrini7Kocaeli University Faculty of Medicine, Department of Medical Genetics, Kocaeli, TurkeyPisa University Faculty of Medicine, Department of Clinical and Experimental Medicine, Division of Hematology, Pisa, ItalyKocaeli University Faculty of Medicine, Department of Medical Genetics, Kocaeli, TurkeyPisa University Faculty of Medicine, Department of Clinical and Experimental Medicine, Division of Hematology, Pisa, ItalyCatania University Faculty of Medicine, Department of Clinical and Molecular Bio-Medicine, Division of Hematology, Catania, ItalySemmelweis University Faculty of Medicine, Department of Obstetrics and Gynecology, Budapest, HungaryCatania University Faculty of Medicine, Department of Clinical and Molecular Bio-Medicine, Division of Hematology, Catania, ItalyPisa University Faculty of Medicine, Department of Clinical and Experimental Medicine, Division of Hematology, Pisa, ItalyObjective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR. Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings. Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.http://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-78309&look4=BortezomibArsenic trioxideNF-κBMDSGene expression |
| spellingShingle | Hakan Savlı Sara Galimberti Deniz Sünnetçi Martina Canestraro Giuseppe Palumbo Balint Nagy Francesco Di Raimondo Mario Petrini Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study Turkish Journal of Hematology Bortezomib Arsenic trioxide NF-κB MDS Gene expression |
| title | Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study |
| title_full | Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study |
| title_fullStr | Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study |
| title_full_unstemmed | Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study |
| title_short | Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study |
| title_sort | bortezomib and arsenic trioxide activity on a myelodysplastic cell line p39 a gene expression study |
| topic | Bortezomib Arsenic trioxide NF-κB MDS Gene expression |
| url | http://www.tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-78309&look4= |
| work_keys_str_mv | AT hakansavlı bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy AT saragalimberti bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy AT denizsunnetci bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy AT martinacanestraro bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy AT giuseppepalumbo bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy AT balintnagy bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy AT francescodiraimondo bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy AT mariopetrini bortezomibandarsenictrioxideactivityonamyelodysplasticcelllinep39ageneexpressionstudy |